Swedbank’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21M | Buy |
64,315
+4,322
| +7% | +$1.41M | 0.02% | 357 |
|
|
2025
Q1 | $16.2M | Buy |
59,993
+4,461
| +8% | +$1.2M | 0.02% | 390 |
|
|
2024
Q4 | $13.1M | Buy |
55,532
+1,803
| +3% | +$424K | 0.02% | 425 |
|
|
2024
Q3 | $14.8M | Buy |
53,729
+33,090
| +160% | +$9.1M | 0.02% | 402 |
|
|
2024
Q2 | $5.02M | Hold |
20,639
| – | – | 0.01% | 534 |
|
|
2024
Q1 | $3.08M | Sell |
20,639
-200,000
| -91% | -$29.9M | 0.03% | 439 |
|
|
2023
Q4 | $42.2M | Hold |
220,639
| – | – | 0.07% | 201 |
|
|
2023
Q3 | $39.1M | Sell |
220,639
-113,303
| -34% | -$20.1M | 0.07% | 195 |
|
|
2023
Q2 | $63.4M | Hold |
333,942
| – | – | 0.11% | 157 |
|
|
2023
Q1 | $66.9M | Sell |
333,942
-92,711
| -22% | -$18.6M | 0.13% | 143 |
|
|
2022
Q4 | $101M | Buy |
426,653
+10,593
| +3% | +$2.52M | 0.22% | 98 |
|
|
2022
Q3 | $83.3M | Sell |
416,060
-23,152
| -5% | -$4.63M | 0.2% | 102 |
|
|
2022
Q2 | $64.1M | Buy |
439,212
+856
| +0.2% | +$125K | 0.14% | 139 |
|
|
2022
Q1 | $71.6M | Buy |
438,356
+1,791
| +0.4% | +$292K | 0.13% | 144 |
|
|
2021
Q4 | $74.7M | Buy |
436,565
+67
| +0% | +$11.5K | 0.12% | 148 |
|
|
2021
Q3 | $82.4M | Buy |
436,498
+90,986
| +26% | +$17.2M | 0.15% | 128 |
|
|
2021
Q2 | $58.6M | Buy |
345,512
+5,193
| +2% | +$880K | 0.11% | 174 |
|
|
2021
Q1 | $48M | Buy |
+340,319
| New | +$48M | 0.1% | 190 |
|